Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis
Version of Record online: 25 NOV 2012
Copyright © 2012 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
EMBO Molecular Medicine
Volume 5, Issue 1, pages 105–121, January 2013
How to Cite
Saddoughi, S. A., Gencer, S., Peterson, Y. K., Ward, K. E., Mukhopadhyay, A., Oaks, J., Bielawski, J., Szulc, Z. M., Thomas, R. J., Selvam, S. P., Senkal, C. E., Garrett-Mayer, E., De Palma, R. M., Fedarovich, D., Liu, A., Habib, A. A., Stahelin, R. V., Perrotti, D. and Ogretmen, B. (2013), Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med, 5: 105–121. doi: 10.1002/emmm.201201283
- Issue online: 3 JAN 2013
- Version of Record online: 25 NOV 2012
- Manuscript Accepted: 28 SEP 2012
- Manuscript Revised: 26 SEP 2012
- Manuscript Received: 13 FEB 2012
- Funded Access
As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.